Abraxis BioScience, Inc. (Abraxis) is an integrated biotechnology company. The Company is engaged in the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients treatments for cancer and other critical illnesses. The Company’s portfolio includes protein-based nanoparticle chemotherapeutic compound (Abraxane), which is based on its tumor targeting technology known as the nab technology platform. Abraxis owns the worldwide rights to Abraxane, a next-generation, nanometer-sized, solvent-free taxane that was approved by the United States Food and Drug Administration (FDA) in January 2005 for its initial indication in the treatment of metastatic breast cancer and launched in February 2005. The Company’s product pipeline includes over five clinical oncology and cardiovascular product candidates in various stages of testing and development, including Abraxane and Coroxane for various indications.